Tempest Announces Successful End-of-Phase 2 Meeting With FDA For Amezalpat In First-Line Hepatocellular Carcinoma; Broad Agreement On Pivotal Phase 3 Study Plan, Overall Survival Will Be Primary Study Endpoint
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics (TPST) announced a successful end-of-Phase 2 meeting with the FDA for Amezalpat in first-line hepatocellular carcinoma. There is broad agreement on the pivotal Phase 3 study plan, with overall survival as the primary study endpoint.
August 15, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tempest Therapeutics (TPST) announced a successful end-of-Phase 2 meeting with the FDA for Amezalpat in first-line hepatocellular carcinoma. The agreement on the pivotal Phase 3 study plan, with overall survival as the primary endpoint, is a significant milestone.
The successful end-of-Phase 2 meeting and agreement on the Phase 3 study plan with the FDA is a significant positive development for Tempest Therapeutics. This milestone increases the likelihood of Amezalpat's approval and commercialization, which could positively impact TPST's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100